Table 2. Prospective randomized trials... | American Society of Hematology

Table 2.

Prospective randomized trials of all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL).

Trial	n	Induction	CR (%)	ED (%)	DFS/EFS, 2–3 yrs, (%)
Abbreviations: CR, complete response; ED, early death; DFS, disease-free survival; EFS, event-free survival; ATRA, all-trans retinoic acid; chemo, chemotherapy; MRC, Medical Research Council.
APL91¹³	54	ATRA (+Chemo)	97	9	79
	47	Chemo	81	8	50
APL93¹⁵	109	ATRA → Chemo	95	8	75
	99	ATRA + Chemo	94	7	86
No. Am. Intergroup¹⁴	172	ATRA	72	11	69
	174	Chemo	69	14	29
MRC¹⁶	119	ATRA(5d) → Chemo	70	23	59
	120	ATRA + Chemo	87	12	78

Trial	n	Induction	CR (%)	ED (%)	DFS/EFS, 2–3 yrs, (%)
Abbreviations: CR, complete response; ED, early death; DFS, disease-free survival; EFS, event-free survival; ATRA, all-trans retinoic acid; chemo, chemotherapy; MRC, Medical Research Council.
APL91¹³	54	ATRA (+Chemo)	97	9	79
	47	Chemo	81	8	50
APL93¹⁵	109	ATRA → Chemo	95	8	75
	99	ATRA + Chemo	94	7	86
No. Am. Intergroup¹⁴	172	ATRA	72	11	69
	174	Chemo	69	14	29
MRC¹⁶	119	ATRA(5d) → Chemo	70	23	59
	120	ATRA + Chemo	87	12	78